Methylphenidate Controlled-Delivery Capsules (Equasym™XL, Metadate CD™): A Review of its Use in the Treatment of Children and Adolescents with Attention-Deficit Hyperactivity Disorder

Authors: Anderson, Vanessa R.; Keating, Gillian M.

Source: Pediatric Drugs, Volume 8, Number 5, 2006 , pp. 319-333(15)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Controlled-delivery methylphenidate (methylphenidate CD) [Equasym™XL, Metadate CD™], an oral stimulant, is approved in the US and EU to treat children aged ≥6 years who have been diagnosed with attention-deficit hyperactivity disorder (ADHD).

Once-daily methylphenidate CD is generally well tolerated and effective in the treatment of children and adolescents with ADHD. Methylphenidate CD resulted in superior control of ADHD symptoms compared with osmotic release oral system (OROS^®) methylphenidate over a time period corresponding to that of an average school day in a laboratory classroom. In 3-week clinical trials conducted in a community setting, methylphenidate CD was superior to placebo and noninferior to methylphenidate immediate-release (IR) in the treatment of children and adolescents with ADHD. Thus, methylphenidate CD should be considered an important primary treatment on its own or in addition to behavioral and psychosocial interventions, for when a reduction in ADHD symptoms is required during the school day in preference to the evening.

Keywords: Adis Drug Evaluations; Adolescents; Attention deficit hyperactivity disorder; Children; Controlled release drugs; Methylphenidate

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health, Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2006-01-01